Post-earnings recap
Reported
Thu, Feb 26, 2026
EPS actual
$-0.73
EPS est.
$-0.75
EPS surprise
+2.67%
1-day move
-3.90%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Denali Therapeutics reported a wider loss per share than expected, but did not provide revenue figures. The stock fell 3.9% in reaction to the lack of revenue data and cautious management commentary. Investors may be concerned about the company's ability to navigate current market challenges without clear guidance on future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.73 | N/A | +2.67% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about market conditions impacting performance. They remain committed to their strategic goals, even in the face of current difficulties.
Management highlighted ongoing challenges in the current market environment.
They emphasized a focus on long-term strategies despite short-term setbacks.